A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS

被引：0
|
作者：
Guadalupi, V. [1 ]
Giganti, M. O. [1 ]
Testa, I. [1 ]
Villa, S. [1 ]
Nicolai, N. [1 ]
Biasoni, D. [1 ]
Salvioni, R. [1 ]
Valdagni, R. [1 ]
Bajetta, E. [1 ]
Procopio, G. [1 ]
机构：
[1] Fondazione IRCCS, Ist Nazl Tumori, Milan, Italy
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
278
引用
收藏
页码：1536 / 1536
页数：1
相关论文
共 50 条
  • [1] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [2] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Barata, Pedro C.
    Cooney, Matthew
    Mendiratta, Prateek
    Tyler, Allison
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
  • [3] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Pedro C. Barata
    Matthew Cooney
    Prateek Mendiratta
    Allison Tyler
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 1085 - 1092
  • [4] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [5] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC)
    Taplin, M.
    Ko, Y.
    Regan, M. M.
    Beer, T. M.
    Carducci, M. A.
    Mathew, P.
    Bubley, G.
    Oh, W. K.
    Kantoff, P. W.
    Balk, S. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole
    Ryan, C.
    Harzstark, A.
    Fong, L.
    Lin, A.
    Kilian, C.
    Molina, A.
    Small, E. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
  • [8] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
  • [10] A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, Dana E.
    Shore, Neal
    Antonarakis, Emmanuel S.
    Berry, William R.
    Alumkal, Joshi J.
    Tutrone, Ronald
    Saleh, Mansoor N.
    Redfern, Charles H.
    Hauke, Ralph J.
    Liu, Glenn
    Steinbrecher, Jill Elise
    Danila, Daniel Costin
    Curley, Tracy
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345